Launch of the I-REIVAC-Emergence platform

The launch of the I-REIVAC-Emergence platform is a decisive step forward for French clinical research in vaccinology against emerging infectious diseases.

Last updated on 06 May 2025

The essential

In response to the growing challenges posed by emerging infectious diseases, ANRS Emerging infectious diseases / Inserm and AP-HP announce the launch of the I-REIVAC-Emergence national platform, dedicated to clinical research in vaccinology. Supported by the France 2030 plan, this project will receive €12 million funding over five years, as part of the strategy to prepare for health crises.

The I-REIVAC-Emergence platform, supported by the ANRS Emerging infectious diseases (ANRS MIE) and AP-HP, draws on the F-CRIN I-REIVAC network expertise. This structure of excellence in clinical vaccine research, whose coordination team is based at Hôtel-Dieu Hospital (AP-HP) in Paris, showed its effectiveness during the Covid-19 pandemic through the Covireivac programme. With the I-REIVAC-Emergence platform, France is strengthening the structure of the national I-REIVAC network to be able to rapidly evaluate vaccines developed by academic and industrial partners, and face future outbreaks.

The platform’s strategic objectives to prepare for future healthcare emergencies are to:

  • strengthen clinical research infrastructures by supporting ten clinical investigation centres in nine university hospitals: AP-HP (Cochin and Saint-Antoine hospitals), Dijon, Lyon, Lille, Montpellier, Nantes, Rennes, Saint-Étienne and Tours
  • support research through methodology and management centres (CMG) with expertise in vaccinology
  • prepare and coordinate biological sample management via eight biological resource centres (BRCs), including three coordinating BRCs in conjunction with the ANRS MIE and Bordeaux University Hospital biobank
  • develop interoperability of trial methodology by standard protocols and data sharing in conjunction with the CMGs
  • ensure standardised automated immunomonitoring tests for rapid, reliable assessment of immune responses in six partner laboratories
  • develop and manage the national register of volunteers already including more than 55,000 participants
  • speed up the implementation of clinical trials through an optimised organisation and simplified regulatory processes in conjunction with the CMGs
  • adapt crisis management plans for rapid mobilisation of the I-REIVAC-Emergence platform resources and expertise in the event of an epidemic, in conjunction with the ANRS MIE crisis unit.

I-REIVAC-Emergence is a project to shape French clinical vaccine research. It is part of a national initiative on vaccine research led by Inserm and the French BioCluster for Innovation in Infectious Diseases (BCF2I) (coordinated by Lyonbiopôle), in which Inserm/ANRS MIE and AP-HP are partners. The platform is also in line with European initiatives such as the European Vaccine Hub (EVH) of the Health Emergency Preparedness and Response Authority (HERA), coordinated for France by the Institut Pasteur.

The I-REIVAC-Emergence platform links up with other national platforms funded as part of the France 2030 acceleration strategy for emerging infectious diseases, and also supported by ANRS MIE/Inserm: for example, EMERGEN 2.0, launched on 19 March 2025 (press release), and OPEN-ReMIE (press release), launched on 21 March 2025. An inter-platform committee will be set up to coordinate these national initiatives, particularly in the event of a health crisis.

With I-REIVAC-Emergence, France has an essential platform to tackle future public health challenges. By strengthening existing infrastructures and facilitating collaboration between academia and industry, the project aims to make France a European leader in vaccines preventing emerging infectious diseases.

Press contact

 

About AP-HP

Europe’s leading university hospital centre (CHU), AP-HP and its 38 hospitals are organised into six university hospital groups (AP-HP. Centre – Université Paris Cité; AP-HP. Sorbonne University; AP-HP. Nord – Université Paris Cité; AP-HP. Université Paris-Saclay; AP-HP. Henri-Mondor University Hospitals and AP-HP. Hôpitaux Universitaires Paris Seine-Saint-Denis) and are structured around five Paris Region universities. In close collaboration with major research organisations, AP-HP has eight world-class university hospital institutes (ICM, ICAN, IMAGINE, FOReSIGHT, PROMETHEUS, lnovAND, Re-Connect, THEMA) and France’s largest healthcare data warehouse (EDS). A major player in applied research and innovation in healthcare, AP-HP holds a portfolio of 810 active patents, its clinician-researchers produce more than 11,000 scientific publications every year and nearly 4,400 research projects are currently under development, all sponsors included. In 2020, AP-HP obtained the Carnot Institute label, which rewards the quality of its partnership research: Carnot@AP-HP offers applied and clinical research solutions in the field of healthcare to industrial players. In 2015, AP-HP also set up the Fondation de l’AP-HP, which works directly with healthcare professionals to support the organisation of care, hospital staff and research within AP-HP. http://www.aphp.fr

About ANRS Emerging infectious diseases

the mission of this autonomous Inserm agency is to facilitate, evaluate, coordinate and fund research into HIV/AIDS, viral hepatitis, sexually transmitted infections, tuberculosis and emerging infectious diseases.

Download the press release